ArticleFrontiers in endocrinology2025
Short-term longitudinal clinical, biochemical, and quality of life outcomes of medical or surgical therapy in unilateral primary aldosteronism.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Unilateral primary aldosteronism (uPA) is a surgically curable form of hypertension, frequently associated with resistant hypertension and cerebro-cardiovascular complications. Primary aldosteronism (PA) also negatively affects quality of life (QOL). Objective: This study sought to compare the efficacy of mineralocorticoid receptor antagonists (MRAs) and adrenalectomy (ADX) in the treatment of patients with uPA over time within the same patients and to evaluate the efficacy of MRAs in patients with bilateral PA (bPA). Methods: Subtype diagnosis of PA was based on adrenal vein sampling results. Clinical parameters, including blood pressure, serum potassium (K), active renin concentration (ARC), aldosterone levels, estimated glomerular filtration rate, and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) scores, were investigated before and after MRA treatment in all PA patients, as well as after ADX in patients with uPA. Results: The study included 56 patients with bPA and 20 patients with uPA. Changes in parameters with MRA treatment were similar between patients with and without uPA, except for a greater increase in K in patients with uPA. Among patients with uPA, systolic blood pressure and K improved with MRA treatment and showed further improvement following ADX. Diastolic blood pressure and ARC also improved following MRA treatment, with no significant differences observed compared to ADX. SF-36 scores showed no improvement with MRA treatment, but significantly improved after ADX. Conclusion: The findings showed that ADX generally provides superior clinical, biochemical, and QOL outcomes compared to MRAs in patients with uPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.